- 31 415 I 6 6 21 Points You Are Trying To Develop A Nasal Spray Version Of A Covid Vaccine Which You Believe H 1 (223.34 KiB) Viewed 30 times
... 31. 415 I.. 6 6. (21 points) you are trying to develop a nasal spray version of a covid vaccine, which you believe has the potential to decrease the amount of viral particles, and therefore the transmissibility, of covid from an infected person who received this vaccine compared to someone who received a traditional intramuscular (IM) formulation. Currently, you are studying your candidate nasal formulation and a standard intramuscular formulation in rhesus macaques. 10 animals are randomized to receive one of the two vaccine formulations; then 6 weeks later they are challenged (infected) with a high dose of Sars- CoV2. your primary outcome is the sub-genomic RNA (sgRNA) measured in a nasal wash on day 2 post-challenge. Your data are: 1 1 2 3 Animal ID Vaccine Formulation 4 5 6 7 I 8 9 10 2 Nasal Nasal IM Nasal IM IM Nasal IM IM Nasal Day 2 sgRNA (log10 scale, primary outcome) 1.81 2.34 2.89 1.18 2.99 2.49 3.26 3.09 4.60 3.52 a. What kind of test would be appropriate to use to see if you have evidence that the sgRNA values are different for animals that received a nasal formulation as compared to an intramuscular formulation? What are the assumptions that are important for the test you have chosen? b. conduct the test you chose in part a. give your p-value and confidence interval for the difference.